Cardiofocus Inc.

MARLBOROUGH, Massachusetts, May 9, 2011 - -- Data Presented at Heart Rhythm 2011 Show Durable Pulmonary Vein Isolation of 86% -- CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the transcatheter treatment of Atrial Fibrillation (AF), announced its technology enables a Pulmonary Vein (PV) acute isolation rate of nearly 99%, with approximately 86% of PVs remaining persistently isolated after three months.